Pediatric Oncology
Pediatric Oncology
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
59
Clinical Trials
Pediatric Oncology
N/A
Enrolling
nct/study# NCT02402244 / COG-APEC14B1
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Learn More
Pediatric Oncology
Phase II
Enrolling
nct/study# NCT06064097 / COG-ARAR2221
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Learn More
Pediatric Oncology
Phase II
Enrolling
nct/study# NCT04322318 / COG-AREN1921
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Learn More
Pediatric Oncology
Phase III
Enrolling
nct/study# NCT03067181 / COG-AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Learn More
Pediatric Oncology
Phase III
Enrolling
nct/study# NCT06401330 / COG-AREN2231
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Learn More
Pediatric Oncology
Phase III
Enrolling
nct/study# NCT02582697 / COG-AGCT1532
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.